Yuhan Corporation
000100
株式のランク
#3833
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
株価
$63.22
時価総額
$4.27B
変化（1日）
-3.12%
変化（1年）
-23.57%
国
KR
取引 Yuhan Corporation (000100)
カテゴリー
Healthcare
Yuhan Corporation（000100）の収益
Jun 2026 時点の収益 TTM: $1.72B
Yuhan Corporation の最新の財務報告によると、現在の収益 (TTM) は $1.72B です。2024 年には $1.41B の収益があり、これは 2023 年の $1.44B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Yuhan Corporation の収益履歴（2007 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.72B | 13.61% |
| 2025 | $1.51B | 7.62% |
| 2024 | $1.41B | -2.06% |
| 2023 | $1.44B | 2.04% |
| 2022 | $1.41B | -0.87% |
| 2021 | $1.42B | -4.85% |
| 2020 | $1.49B | 16.39% |
| 2019 | $1.28B | -6.01% |
| 2018 | $1.36B | -0.59% |
| 2017 | $1.37B | 25.25% |
| 2016 | $1.10B | 14.05% |
| 2015 | $960.45M | 3.29% |
| 2014 | $929.82M | 3.74% |
| 2013 | $896.29M | 22.88% |
| 2012 | $729.40M | 24.46% |
| 2011 | $586.04M | -0.96% |
| 2010 | $591.75M | 6.18% |
| 2009 | $557.33M | 17.68% |
| 2008 | $473.59M | -10.14% |
| 2007 | $527.01M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $23.54B | 1,268.60% |
DE
|
|
| $23.73B | 1,280.21% |
DE
|
|
| $29.24B | 1,600.31% |
JP
|
|
| $5.85B | 240.11% |
CH
|
|
| $6.34B | 268.81% |
IN
|
